ANDOVER, Mass. — TransMedics Group has appointed Fernando Araujo as Chief Financial Officer, effective Sept. 21, as the company continues to expand its organ transplant technology and international operations.
Araujo brings more than 20 years of public-company finance experience at GE HealthCare, General Electric and 3M. He succeeds Gerardo Hernandez, who will transition to Commercial Strategic Advisor, LATAM, where he will lead TransMedics’ expansion into Latin America.
TransMedics also reiterated its full-year 2026 revenue guidance of $737 million to $757 million, representing approximately 22% to 25% year-over-year growth.
Araujo most recently served as Chief Financial Officer of GE HealthCare’s Advanced Imaging Solutions segment, a $16 billion business combining the company’s Imaging and Advanced Visualization Solutions operations with its global supply chain and service organizations.
He previously served as GE HealthCare’s Corporate Finance CFO and as Senior Vice President of Finance for Enterprise Operations at 3M. During a 17-year career at General Electric, he also held several senior finance and CFO roles across healthcare, energy and Latin American operations.
“Fernando joins TransMedics at a growth inflection point,” said Waleed Hassanein, M.D., President and Chief Executive Officer. “We are focused on scaling rapidly across strategic dimensions of our business to stimulate U.S. NOP heart and lung growth, expand our product pipeline with OCS Kidney and OCS Gen-3.0, drive operating leverage, and build out our international NOP commercial and logistics footprint across Europe. Fernando’s track record of scaling finance operations at complex, global healthcare businesses is well aligned with what’s ahead of TransMedics, and we are confident he will help us capitalize on the significant growth opportunities ahead. I am delighted to welcome Fernando to TransMedics.”
“I am excited to join TransMedics at such an important stage in the Company’s growth,” Araujo said. “TransMedics has differentiated technology, an industry leadership position, and multiple near-term potential growth catalysts. I look forward to partnering with the leadership team to support disciplined execution, expand operating leverage, and create lasting value for shareholders while advancing the Company’s mission for transplant patients.”
Hassanein also thanked Hernandez for his leadership over the past two years and said he would now focus on the company’s Latin American commercial expansion.
“I would like to express my sincere gratitude for Gerardo’s partnership and leadership over the past two years; his contributions have been central to our operational execution,” Hassanein said. “Our LATAM commercial opportunity is beginning to materialize, and Gerardo is uniquely positioned to lead an early entry in the region– working directly with me and our international commercial leadership team to accelerate our expansion and capture this high-value opportunity.”
The 2026 guidance excludes any revenue contribution from TransMedics’ recent strategic investment in PAD Aviation Service GmbH. The company said it expects to revisit its outlook when it reports third-quarter 2026 results.
